"Throughout our company's long history as a leader in influenza prevention, we have remained committed to delivering safe and effective vaccines to as many eligible people as possible," said Gregg Sylvester, MD, Chief Medical Officer at Seqirus. 2,3 Cell-based influenza vaccine technology may offer additional advantages over the standard influenza manufacturing process, including increased scalability and production speed in the event of an influenza pandemic. 2Ĭell-based influenza vaccines are designed to produce an exact match to WHO-selected influenza virus strains by avoiding egg-adapted changes, and therefore may have the potential for greater vaccine effectiveness. 2 Traditional egg-based vaccine production can cause the strain to mutate at several steps throughout the manufacturing process, which may lead to an antigenic mismatch between the circulating strains and the inactivated influenza strains contained within the seasonal influenza vaccine. "The FLUCELVAX QUADRIVALENT expanded age indication for children as young as six months of age now allows all eligible people to receive a differentiated influenza vaccine option."įLUCELVAX QUADRIVALENT utilizes a cell-based influenza vaccine manufacturing process, an alternative to traditional egg-based manufacturing. "As one of the world's largest influenza vaccine manufacturers, we continually seek to apply new technologies and evolve our vaccine portfolio to help address challenges associated with seasonal influenza vaccine effectiveness," said Dave Ross, Vice President, North America Commercial Operations at Seqirus. Phase 3 study of a cell-based influenza vaccine in this population. 5 These data, presented at the Pediatric Academic Society (PAS) virtual Annual Meeting on May 1, 2021, represent the first U.S. The expanded age indication is supported by a Phase 3 clinical study demonstrating that FLUCELVAX QUADRIVALENT was as safe and immunogenic as a standard quadrivalent seasonal influenza vaccine (QIV) in children six months to 4 With this approval, FLUCELVAX QUADRIVALENT, the first and only cell-based influenza vaccine in the U.S., is now indicated for everyone eligible to receive an influenza vaccine in the U.S. Food and Drug Administration (FDA) has approved FLUCELVAX ® QUADRIVALENT (Influenza Vaccine), the company's cell-based quadrivalent influenza vaccine, for an expanded age indication for children as young as six months old. 15, 2021 /PRNewswire/ - Seqirus, a global leader in influenza prevention, and a business of CSL Limited (ASX: CSL), today announced that the U.S.